Bullous Pemphigoid: Cause and Treatment
Cause
Bullous pemphigoid is an autoimmune disease caused by IgG autoantibodies directed against BP180 (BPAG2/type XVII collagen) and/or BP230 (BPAG1) proteins located in the basement membrane zone 1. These autoantibodies activate complement, triggering mast cell degranulation and inflammatory cell infiltration (eosinophils and neutrophils), which release mediators that damage the basement membrane and cause subepidermal blister formation 2.
Risk factors include:
- Advanced age (typically >70 years)
- Recent drug exposure (within 1-6 months prior to onset)
- Neurological disorders (particularly cerebral infarctions and dementia) 3
Treatment
For Extensive Disease (>10 new blisters/day): Use topical clobetasol propionate 0.05% cream 40g daily as first-line therapy, NOT systemic steroids 4
This represents a paradigm shift from traditional practice. The landmark RCT demonstrated that clobetasol propionate cream (20g applied twice daily to entire body surface) was superior to oral prednisone 1 mg/kg/day for extensive disease, with significantly better disease control, fewer adverse events, and lower mortality 4. Apply to both affected and unaffected skin.
For Moderate Disease (<10 new blisters/day):
Either topical clobetasol propionate 0.05% cream OR oral prednisone 0.5 mg/kg/day are equally effective 4. Given the safety profile, topical therapy should be preferred when feasible.
For Localized Disease:
Superpotent topical corticosteroids alone are sufficient 5.
Adjuvant Immunosuppressants:
When systemic steroids are required or for steroid-sparing effect:
- Azathioprine (up to 2.5 mg/kg/day): Evidence is conflicting; one RCT showed 45% reduction in cumulative steroid dose, while another showed no benefit with increased adverse effects 4
- Mycophenolate mofetil (1g twice daily): Equally effective as azathioprine but with different side effect profile (more infections vs. hepatotoxicity with azathioprine) 4
- Doxycycline, methotrexate, dapsone: Alternative steroid-sparing agents 3
Second/Third-Line Options for Severe or Refractory Disease:
- Rituximab (anti-CD20 antibody)
- Cyclophosphamide
- Intravenous immunoglobulins
- Immunoadsorption 3
Recent Breakthrough:
Dupilumab (IL-4/IL-13 inhibitor) received FDA approval for moderate/severe bullous pemphigoid 6, representing the first biologic specifically approved for this indication.
Treatment Duration and Monitoring
Average treatment duration: 4-12 months 1. Discontinue therapy only after patients remain symptom-free for 1-6 months on minimal therapy (prednisone ≤0.1 mg/kg/day or clobetasol 10g/week) 1.
Critical monitoring points:
- Anti-BP180 IgG levels at days 0,60, and 150 predict outcomes
- A decrease of ≤20% in anti-BP180 IgG between days 0-60 predicts relapse 1
- Check DIF and/or BP180 ELISA before stopping treatment; if BP180 ELISA >27 U/mL, relapse risk is increased 1
Follow-up schedule:
- Weekly during first month
- Monthly for next 3 months
- Every 2 months thereafter until treatment stopped 1
Essential Supportive Care
For patients on systemic steroids ≥7.5mg daily for ≥3 months:
- Proton pump inhibitor for gastric protection
- Calcium and vitamin D supplementation PLUS bisphosphonate from treatment initiation (proven effective in preserving bone density) 4
- Note: Calcium impairs absorption of mycophenolate and bisphosphonates—administer at different times 4
- Monitor for adrenal insufficiency even after topical steroid cessation 1
Critical Pitfalls
- Do NOT default to high-dose systemic steroids for extensive disease—topical clobetasol is superior 4
- Patients with BP have significantly increased mortality compared to controls; proper specialized management is essential 1
- Reappearance of pruritus, excoriations, or inflammatory lesions warrants immediate reassessment for relapse 1
- Follow-up visit at 3 months post-discontinuation is critical as this period captures most relapses 1